Security key
28617K101
Eledon Pharmaceuticals, Inc. - Common Stock (ELDN)
CUSIP: 28617K101
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 40,843,175
- Total 13F value
- $110,685,079
- Share change
- +2,389,286
- Put/Call ratio
- 62%
- SEC-reported price per share
- $2.71
- Number of holders
- 85
- Value change
- +$5,557,133
- Number of buys
- 48
- Number of sells
- 41
- Shares outstanding
- 81,270,267
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
85
Top holders
10
ELDN full security history
Ownership snapshot
Full 13F holder table
Eledon Pharmaceuticals, Inc. SEC filings
Eledon Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ELDN - Eledon Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
BVF INC/IL
Comparable rows
2/15
Latest evidence
31 Mar 2025
13D/G
3/4/5
13F
Lead comparable stake: 5%
13 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 2
ARMISTICE CAPITAL, LLC
5%
Frazier Life Sciences Public Fund...
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
Reported 13D/G
· 31 Dec 2024
|
$10,259,798
3,137,553 shares
|
$0 | 31 Dec 2024 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
James N. Topper
|
2%
Reported 13D/G
· 31 Dec 2024
|
$3,847,923
1,176,735 shares
|
$0 | 31 Dec 2024 |
| BVF PARTNERS L P/IL |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$4,047,373
1,319,428 shares
mixed-class rows
|
— | 29 Oct 2024 |
| BVF INC/IL |
13F
Company
|
—
denominator unverified
|
$21,334,226
6,293,282 shares
|
— | 31 Mar 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
denominator unverified
|
$12,089,886
3,566,338 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$10,011,100
2,953,127 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
85
Shares
40,843,175
Rows available
85
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
83
Q2 2025 holders
85
Holder diff
2
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|